David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.